To quantify the tumor-infiltrating CD4+, CD8+ T cells and CD11c+ DCs, the tumor samples on day 7 after treatment initiation, a representative time-point for Tregs depletion and tumor growth inhibition, were analyzed by flow cytometry. Here, ITGAX is linked to neoplasm.